The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan

Pardeep S Jhund, John J V McMurray

ABSTRACT

Inhibition of neurohumoral pathways such as the renin angiotensin aldosterone and sympathetic nervous systems is central to the understanding and treatment of heart failure (HF). Conversely, until recently, potentially beneficial augmentation of neurohumoral systems such as the natriuretic peptides has had limited therapeutic success. Administration of synthetic natriuretic peptides has not improved outcomes in acute HF but modulation of the natriuretic system through inhibition of the enzyme that degrades natriuretic (and other vasoactive) peptides, neprilysin, has proven to be successful. After initial failures with neprilysin inhibition alone or dual neprilysin-angiotensin converting enzyme (ACE) inhibition, the Prospective comparison of angiotensin receptor neprilysin inhibitor (ARNI) with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) trial demonstrated that morbidity and mortality can be improved with the angiotensin receptor blocker neprilysin inhibitor sacubitril/valsartan (formerly LCZ696). In comparison to the ACE inhibitor enalapril, sacubitril/valsartan reduced the occurrence of the primary end point (cardiovascular death or hospitalisation for HF) by 20% with a 16% reduction in all-cause mortality. These findings suggest that sacubitril/valsartan should replace an ACE inhibitor or angiotensin receptor blocker as the foundation of treatment of symptomatic patients (NYHA II–IV) with HF and a reduced ejection fraction. This review will explore the background to neprilysin inhibition in HF, the results of the PARADIGM-HF trial and offer guidance on how to use sacubitril/valsartan in clinical practice.

The renin angiotensin aldosterone system (RAAS) system is at the core of the pathophysiology of heart failure (HF) and its modulation is central to altering the disease process in HF with reduced ejection fraction (HF-REF). Successive randomised controlled trials have demonstrated that blockade of RAAS improves morbidity and mortality in patients with HF-REF.1–3 The prognosis of HF-REF has been improved as a consequence, although it remains poor4 as it remains a complex syndrome involving a multitude of neurohormonal pathways. Therefore, further therapies to improve outcomes in these patients are needed.

THE NATRIURETIC PEPTIDE SYSTEM

The natriuretic peptide system counter regulates the detrimental effects of the upregulation of RAAS that occurs in HF-REF, inhibits secretion of arginine vasopressin and modulates the autonomic nervous system in ways that are likely to be beneficial in this syndrome.5 Sodium and water retention and vasoconstriction caused by activation of RAAS and the sympathetic nervous system, and the action of vasopressin, lead to increased ventricular preload and afterload and elevated wall stress which in turn lead to production of pre-pro B-type natriuretic peptide (BNP) which is cleaved to BNP and N-terminal proBNP (NT-proBNP). The release of natriuretic peptides may also be determined by the levels of other neurohormones such as angiotensin II and endothelin.6 The peptide BNP acts to promote natriuresis and vasodilation (NT-proBNP is physiologically inactive). Atrial stretch leads to the production of pre-proatrial or A-type natriuretic peptide and ultimately atrial natriuretic peptide (ANP) which has similar biological properties to BNP. Urodilatin (which is structurally related to ANP), is derived from the same precursor in the kidneys.7 C-type natriuretic peptide (CNP) is released from endothelial cells and acts in a paracrine fashion but is only found in low concentrations in circulating blood.8 Two strategies have been employed to try and improve outcomes in HF-REF via modulation of this pathway. The first is the administration of exogenous natriuretic peptides. Nesiritide, a recombinant human BNP, initially showed promising beneficial effects on haemodynamics and natriuresis in patients with HF-REF.9 However, in a large-scale randomised controlled trial, nesiritide failed to improve outcomes (though it did improve dyspnoea).9 Although carperitide (recombinant ANP) is used as a treatment for acute HF in Japan, there is no robust evidence supporting this practice.10 The second strategy is to inhibit the breakdown of natriuretic peptides. ANP, BNP, CNP and urodilatin are cleaved and inactivated by a membrane bound endopeptidase, neprilysin (as well as insulin degrading enzyme). Neprilysin is found in a number of tissues but in especially high concentrations in the kidney. Natriuretic peptides are also cleared via the natriuretic peptide clearance receptor ( NPRC and N PRC3).

INITIAL NEPRILYSIN INHIBITORS

Initial attempts at inhibiting neprilysin using an oral (racecodotril)11 and intravenous (candoxatril) formulation were successful in promoting natriuresis and increasing urinary excretion of ANP. A further neprilysin inhibitor (ecadotril) had similar effects.12 However, a study of chronic use of the oral prodrug candoxatril showed that the initial reduction in blood pressure was not sustained and therefore development was stopped.13 This might be explained by the finding that neprilysin also breaks down angiotensin II.13–15 Therefore inhibiting neprilysin alone, while raising natriuretic peptides levels, also increases angiotensin II levels (and other substrates for neprilysin such as...
endothelin, vasopressin, bradykinin, etc) potentially counteracting the actions of the former peptides.

**DUAL NEPRILYSIN AND ACE INHIBITION**

The solution to the problem of lone neprilysin inhibition appeared to be dual blockade of RAAS and the natriuretic peptide system (figure 1). As ACE inhibitors are known to improve outcomes it seemed logical to combine an ACE inhibitor with a neprilysin inhibitor. The combined ACE and neprilysin inhibitor omapatrilat was studied in a large randomised controlled trial against enalapril 10 mg twice daily in the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) trial.18 The primary end point, death from any cause or HF hospitalisations were not reduced by omapatrilat. Although other secondary end points suggested a benefit with omapatrilat (death from any cause or cardiovascular (CV) hospitalisation was 9% lower in the omapatrilat group) the rate of angio-oedema was much higher in the omapatrilat group. Both ACE and neprilysin break down bradykinin and omapatrilat also inhibits aminopeptidase P which also catabolises bradykinin. Therefore, unintended excessive potentiation of bradykinin and resultant high rates of serious angio-oedema led to the discontinuation of the clinical development of this drug.

**ANGIOTENSIN RECEPTOR BLOCKER NEPRILYSIN INHIBITORS**

Combining an angiotensin receptor blocker (ARB) and a neprilysin inhibitor was the logical next step and potential solution to the problem encountered with omapatrilat. The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan (formerly known as LCZ696) was designed with the aim of inhibiting neprilysin while blocking the adverse effects of RAAS and reducing bradykinin potentiation.19–21 The drug LCZ696 is made of the ARB valsartan and neprilysin inhibitor prodrug sacubitril. As the active metabolite of sacubitril, sacubitrilat (LBQ657), does not inhibit aminopeptidase P, the risk of angio-oedema was expected to be lower than with omapatrilat.19–21 Given twice daily, sacubitril/valsartan leads to sustained neprilysin and RAAS inhibition over a 24 h period addressing one limitation of the OVERTURE trial in which omapatrilat was given as a single large dose once daily.22 That approach may have contributed to the significant early postdose hypotension seen with omapatrilat but did not provide sustained inhibition of ACE and neprilysin over 24 h. The systemic exposure delivered by sacubitril/valsartan 97 mg/103 mg (200 mg LCZ696) is equivalent to 160 mg of valsartan and neprilysin is almost completely inhibited for up to 12 h.19–21

The Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) was conducted to test whether 97 mg/103 mg twice daily of sacubitril/valsartan was superior to enalapril 10 mg twice daily in reducing the primary end point of CV death or HF hospitalisation.22–24 All randomised patients completed a run-in period of 6–8 weeks during which it was required that the target dose of both drugs was tolerated prior to randomisation. Each treatment period (enalapril and sacubitril/valsartan) included a washout period to avoid simultaneous neprilysin and ACE inhibition and the potential risk of angio-oedema (patients with a history of angio-oedema were also excluded). The trial was terminated early, on the recommendation of the Data Monitoring Committee, due to a sustained and highly significant reduction in the risk of the primary composite end point (CV death or HF hospitalisation) and in CV mortality in the sacubitril/valsartan group compared with the enalapril group. At the end of the trial, there was a 20% relative risk reduction in the primary end point and each of its components, as well as a 16% reduction in all-cause mortality. The two major modes of CV death, sudden death and death from worsening HF, were equally and significantly reduced.25 Both first hospitalisations for HF and total (including repeat) hospitalisations were also reduced by 21% and 23%, respectively (figure 2).26 Therefore, for every 1000 patients switched
from enalapril to sacubitril/valsartan, over a median of 27 months, there would be: 47 less primary end points (CV death or HF hospitalisations), 33 less CV deaths, 28 less first hospitalisations for HF (53 less total hospitalisations for HF) and 32 less deaths from any cause.24 No convincing or consistent interaction between any of the subgroups and study outcomes were observed.24 There was no statistically significant difference in the rate of angio-oedema with sacubitril/valsartan although numerically more cases were observed than in the enalapril group (19 patients in the sacubitril/valsartan group and 10 cases in the enalapril group, p=0.13).24 Hypotension was significantly more common with sacubitril/valsartan than with enalapril (14% vs 9% in the in the sacubitril/valsartan and enalapril groups respectively, p<0.001), although this rarely led to study-drug discontinuation (0.9% and 0.7% in the sacubitril/valsartan and enalapril groups respectively, p=0.38). Conversely, renal dysfunction, hyperkalaemia and cough were less common with sacubitril/valsartan than with enalapril. Subsequent analyses of PARADIGM-HF have confirmed that the relative reductions in morbidity and mortality and differential rates of adverse events were similar across all ages27 (figure 3) and baseline risk of death as determined by risk-scoring systems.28

**ROBUSTNESS OF RESULTS OF PARADIGM-HF AND REGULATORY APPROVAL**

Regulatory approval of a new drug requires demonstration of effectiveness and safety in either two trials with a two-sided p<0.05 OR a single, large, internally consistent, multicentre study with p<0.001.25 PARADIGM-HF fulfils these criteria. It was large (8399 patients randomised), highly statistically significant (p=0.0000004), internally consistent (lack of subgroup interactions), multicentre (sites were located in 47 countries), and there were large effects on morbidity and mortality (CV death or hospitalisation for HF was reduced by 20% and all-cause mortality by 16%). If we ignore the argument that to repeat the trial would be unethical, to achieve such a statistically significant result on the primary end point would require four

![Figure 2](image1.png)

**Figure 2** Effect of sacubitril/valsartan on the rate of heart failure (HF) hospitalisations as a time to first event analysis and as a recurrent event analysis of total hospitalisations for.26

![Figure 3](image2.png)

**Figure 3** Effect of sacubitril/valsartan on the rate of primary end point and component and all-cause mortality in patients randomised in the PARADIGM-HF trial according to age group.13 p for interaction for cardiovascular (CV) death or heart failure (HF) hospitalisation=0.94, for CV death p for interaction=0.92, for HF hospitalisation p for interaction=0.81 and all-cause death p for interaction=0.99. PARADIGM-HF, Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure.
or five trials each with a \( p \) value of \(<0.05\) to have the same strength of evidence as provided by a single trial with a \( p \) value of \( 0.0000004\) (table 1). Put another way, if sacubitril/valsartan was in fact no better than enalapril the chances of observing the treatment difference that was found in PARADIGM-HF is less than one in a million.\(^3\) We believe that this finding creates a unique question for the HF guideline committee. ‘Level A’ evidence conventionally requires data from multiple randomised trials or a well conducted meta-analysis (table 2). Usually, a solitary randomised trial would confer a B level of evidence. Does the robustness of the findings of PARADIGM-HF equate to two trials or a meta-analysis?

**WHO SHOULD BE PRESCRIBED SACUBITRIL/VALSARTAN?**

The only evidence for the use of sacubitril/valsartan is in patients with HF-REF. An outcomes trial of sacubitril/valsartan versus valsartan in patients with HF and preserved ejection fraction, the Prospective comparison of ARni with Argol Black Outcomes in heart failure with preserved ejection fraction (PARAGON-HF) is currently still recruiting (ClinicalTrials.gov Identifier: NCT01920711). We also do not have robust data on the use of this drug in hospitalised patients (although some data are available)\(^3\) a trial is under way (ClinicalTrials.gov Identifier: NCT02661217) or those with HF complicating an acute myocardial infarction. Therefore, if we consider the inclusion and exclusion criteria of the PARADIGM-HF trial, sacubitril/valsartan can be given to: adult patients with HF, New York Heart Association (NYHA) II–IV and a reduced ejection fraction \((\leq 40\%)\) on \( \beta \)-blocker and MRA as recommended by guidelines, with a systolic blood pressure of \( \geq 100 \text{ mm Hg} \) and estimated glomerular filtration rate \((\text{eGFR}) \geq 30 \text{ mL/min/1.73 m}^2\) and potassium \( \leq 5.2 \text{ mmol/L} \) (figure 4). The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) prescribing information is consistent with these groups.\(^3\)\(^2\)\(^\text{-}^3\)\(^2\)\(^\text{-}^4\) Nevertheless, we do not have robust data on the use of this drug in hospitalised patients (although some data are available)\(^3\) the trial is underway (ClinicalTrials.gov Identifier NCT01920711) or those with HF complicating an acute myocardial infarction. Therefore, if we consider the inclusion and exclusion criteria of the PARADIGM-HF trial, sacubitril/valsartan can be given to: adult patients with HF, New York Heart Association (NYHA) II–IV and a reduced ejection fraction \((\leq 40\%)\) on a \( \beta \)-blocker and MRA as recommended by guidelines, with a systolic blood pressure of \( \geq 100 \text{ mm Hg} \) and estimated glomerular filtration rate \((\text{eGFR}) \geq 30 \text{ mL/min/1.73 m}^2\) and potassium \( \leq 5.2 \text{ mmol/L} \) (figure 4). The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) prescribing information is consistent with these groups.\(^3\)\(^2\)\(^\text{-}^3\)\(^2\)\(^\text{-}^4\)

**Table 1** Number of trials with a \( p \) value \(<0.05\) to provide the same level of evidence as PARADIGM-HF on the primary outcome and cardiovascular death

<table>
<thead>
<tr>
<th>Number of trials with ( p ) (&lt;0.05) showing efficacy</th>
<th>( p ) value required by 1 trial to provide the same strength of evidence</th>
<th>PARADIGM-HF ( p ) value for primary end point</th>
<th>PARADIGM-HF ( p ) value for CV death</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 trial</td>
<td>0.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2 trials*</td>
<td>0.00125*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 trials</td>
<td>0.00003125</td>
<td>0.000008 (equivalent to 2–3 trials at ( p )=0.05)</td>
<td></td>
</tr>
<tr>
<td>4 trials</td>
<td>0.00000078</td>
<td>0.0000004 (equivalent to 4–5 trials at ( p )=0.05)</td>
<td></td>
</tr>
<tr>
<td>5 trials</td>
<td>0.0000000195</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Based on the formula \((0.025)^n \times 2\) where \( n \) is the number of trials required (5 Pocock personal communication 2015).

\( *\)Usual regulatory requirement—2 trials at \( p \)=0.05 or 1 trial at \( p \)=0.00125.

**Table 2** Class of recommendation and level of evidence definitions used by major guideline bodies

<table>
<thead>
<tr>
<th>Classes of recommendations</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class I</td>
<td>Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.</td>
</tr>
<tr>
<td>Class II</td>
<td>Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.</td>
</tr>
<tr>
<td>Class IIa</td>
<td>Usefulness/efficacy is less well established by evidence/opinion.</td>
</tr>
<tr>
<td>Class IIb</td>
<td>Usefulness/efficacy is less well established by evidence/opinion.</td>
</tr>
<tr>
<td>Class III</td>
<td>Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.</td>
</tr>
</tbody>
</table>

Levels of evidence

<table>
<thead>
<tr>
<th>Level of evidence</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level of evidence A</td>
<td>Data derived from multiple randomised clinical trials or meta-analyses.</td>
</tr>
<tr>
<td>Level of evidence B</td>
<td>Data derived from a single randomised clinical trial or large non-randomised studies.</td>
</tr>
<tr>
<td>Level of evidence C</td>
<td>Consensus of opinion of the experts and/or small studies, retrospective studies, registries.</td>
</tr>
</tbody>
</table>

from the FDA and EMA, cost-effectiveness analyses in private and public healthcare systems confirm that sacubitril/valsartan is cost-effective.

**WHEN SHOULD A PATIENT BE PRESCRIBED SACUBITRIL/VALSARTAN?**

Currently the prescribing information from FDA notes that sacubitril/valsartan should be used in patients in place of an ACE inhibitor or other ARB that is, that patients on these treatments should be switched to ARN1.\(^2\) We are lacking evidence for patients with newly diagnosed HF-REF. Should they be established on an ACE inhibitor (or ARB) for at least 1 month after which time they would have been eligible for PARADIGM-HF that is, to switch to sacubitril/valsartan? The FDA seems to have decided otherwise as their labelling also gives recommendations on how to start sacubitril/valsartan in ACE inhibitor/ARB-naïve patients (see below).\(^2\) This is probably logical (if not entirely evidence-based), as the lower risks of renal dysfunction and hyperkalaemia with sacubitril/valsartan may enable more patients to achieve optimal RAAS inhibition. Furthermore, conducting a trial in ACE inhibitor/ARB-naïve patients would be nearly impossible—recruitment would be slow (given the much smaller number of patients with incident heart failure) and cross-over from the ACE inhibitor group to the sacubitril/valsartan group is likely to be very high, confounding interpretation of outcomes. In the Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients (TITRATION) study\(^1\) of dose escalation strategies of sacubitril/valsartan (\( N=498\) patients who were ACE inhibitor or ARB-naïve (7%) and hospitalised (11%) were included. Rates of adverse events were similar to those reported in PARADIGM-HF.

Furthermore, apart from these practical considerations, there is no plausible scientific reason to believe the results of such a trial would be different than PARADIGM-HF and an analysis of the PARADIGM-HF trial by subgroup of duration of HF (those with HF for \( \leq 1 \text{ year} \), 1–5 years and >5 years) revealed no interaction between duration of HF and benefit from sacubitril/valsartan (\( p \) for interaction for the primary outcome=0.27).\(^2\)
HOW SHOULD SACUBITRIL/VALSARTAN BE PRESCRIBED?

Sacubitril/valsartan should not be given in conjunction with another ARB or renin inhibitor (because of the risk of renal impairment and hyperkalaemia) or an ACE inhibitor (risk of renal impairment, hyperkalaemia and angio-oedema). Due to the potential risk of angio-oedema when used concurrently with an ACE inhibitor, sacubitril/valsartan must not be started for at least 36 h after discontinuing an ACE inhibitor. Patients and carers should discard any remaining doses to reduce the risk of accidental overdosing. The starting dose of sacubitril/valsartan is 49 mg/51 mg twice daily. This should be reduced in certain groups (Table 3). The dose should be doubled every 2–4 weeks as tolerated by the patient to the maximum dose of 97 mg/103 mg twice daily.

Patients should also be prescribed other evidence-based drugs (β-blocker, mineralocorticoid receptor antagonist, ivabradine and digoxin) and devices (cardiac resynchronisation therapy (CRT), implantable cardioverter defibrillator (ICD), LVAD, left ventricular assist device).

SIDE EFFECTS AND CAUTIONS

Renal function and potassium should be monitored as for any other RAAS blocker. Similarly blood pressure should also be monitored and we would suggest that the drug is not started in those with a systolic blood pressure of <100 mm Hg in keeping with the exclusion criteria of the trial. In the event of the development of hypotension, renal impairment or hyperkalaemia, evaluation of the potential causes should be sought and appropriate changes made. For example, reducing the dose of other non-essential blood pressure-lowering drugs, adjusting the dose of diuretics, discontinuing other drugs such as non-steroidal anti-inflammatory drugs. Of course dose reduction or discontinuation of sacubitril/valsartan should also be considered in these scenarios after assessment of the patient. The development of angio-oedema should lead to immediate discontinuation and treatment with appropriate therapy until it has resolved. Permanent treatment discontinuation was not common in the PARADIGM-HF trial with rates of discontinuation similar in the sacubitril/valsartan group and the enalapril group for hypotension and hyperkalaemia (all <1%).

Rates of discontinuation for renal impairment were lower in the sacubitril/valsartan group compared with the enalapril group (0.7% vs 1.4% respectively, p=0.002).

One final issue worthy of note is that of treatment monitoring. Monitoring the treatment and prognosis of patients with HF by tracking natriuretic peptides is still an area of great interest. Sacubitril/valsartan increases levels of circulating BNP therefore BNP is not useful for monitoring the prognosis of these patients. NT-proBNP is still useful as changes in the levels of this inactive peptide continue to reflect reduced pre-proBNP secretion as a result of reduction in wall stress. Nephrilysin has a higher affinity for other natriuretic peptides such as ANP and CNP than it does for BNP. Therefore, other natriuretic peptides may be more useful to monitor treatment response and the level of nephrilysin inhibition, although whether this would predict prognosis is unclear.

HEART FAILURE WITH PRESERVED EJECTION FRACTION

There is also experience with sacubitril/valsartan in heart failure with preserved ejection fraction (HF-PEF). In the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejeCtioN fraccion (PARAMOUNT) trial, 301 patients with HF-PEF were randomised to valsartan or sacubitril/valsartan. NT-proBNP fell in the latter group along with reductions in NYHA class and left atrial volumes. On the basis of these findings and the favourable effects seen in PARADIGM-HF a large multicentre randomised outcomes trial of sacubitril/valsartan versus valsartan, PARAGON-HF, is currently recruiting.

SUMMARY

Even in patients with HF-REF with mild symptoms, apparently ‘stable’ on conventional treatment, it is clear that morbidity and mortality can be reduced in those patients receiving sacubitril/valsartan. Further long term studies are required to establish the potential long term benefit of sacubitril/valsartan in the treatment of heart failure.
mortality remains high and that substitution of sacubitril/valsartan for an ACE inhibitor leads to rapid and substantial improvement in outcomes. Therefore, it is our view that an ARNI should replace an ACE inhibitor (or an ARB) as a foundation of treatment for HF-REF and already this view is reflected in new guidelines. 

The results of the PARAGON-HF trial will determine whether sacubitril/valsartan has any place in the management of HF-PEF. The speed of adoption of sacubitril/valsartan will depend on a number of different factors, including cost-effectiveness.

**Contributors** PSJ and JVM wrote and revised the manuscript.

**Competing interests** PSJ has consulted for Novartis. JVM’s employer, the University of Glasgow, was/is being paid for his time spent as Executive Committee member/cochair of PARADIGM-HF and PARGON-HF.

**Provenance and peer review** Commissioned; externally peer reviewed.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**REFERENCES**


10. Hata N, Seino Y, Tsutamoto T. The results of the PARAGON-HF trial will determine whether sacubitril/valsartan has any place in the management of HF-PEF. The speed of adoption of sacubitril/valsartan will depend on a number of different factors, including cost-effectiveness.

**Review**


24. (NICE) NI for CE. Appraisal consultation document Sacubitril valsartan for treating heart failure patients. scottishmedicines.org.uk/SMC_Advice/Advice/1132_16_sacubitril_valsartan_Entresto


